Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pravastatin and e-PROs for severe radiation-induced breast fibrosis
2024-515342-16-00Phase 2Authorised
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of pravastatin in Breast fibrosis and breast cancer (2 arms), sponsored by Institut du Cancer de Montpellier. Primary endpoint: Breast-related quality of life improvement rate at 12 months. Planned start Sep 2024; status: authorised.
02
Drugs
pravastatin
03
Conditions
Breast fibrosisbreast cancer
Beyond the preview
Go deeper on 2024-515342-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515342-16-00.